Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...
The U.S. Food and Drug Administration announced it will relax certain rules for approving low-cost versions of some high-priced medications to reduce costs.
2don MSN
FDA to streamline approvals for generic biological drugs in latest move targeting health costs
The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to ...
The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...
The steady approval of new biosimilars in recent years provides additional safe, effective, and cost-effective options for ...
By Patrick Wingrove and Puyaan Singh (Reuters) -AbbVie said on Friday the Trump administration was pushing for steeper cuts ...
HealthDay on MSN
FDA to Ease Copycat Drug Rules, Speeding Access to Cheaper Drugs
Key Takeaways Federal regulators will no longer require costly clinical trials for most biosimilars, speeding up approvalThe ...
This analysis reviews the history and current status of biosimilar regulation in the US, concluding that changing the FDA’s interchangeability standards—as proposed by some policy makers—is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback